Crohn's Disease News and Research

Latest Crohn's Disease News and Research

RedHill Biopharma to initiate phase III trial of RHB 104 in Crohn's disease patients

UCF College of Medicine professor Dr. Saleh Naser soon will participate in a clinical trial to test whether a new antibiotic therapy acquired by RedHill Biopharma can be used to treat Crohn's disease patients.

18 Sep 2013

FDA grants orphan drug designation to Soligenix’s SGX94 for treatment of Acute Radiation Syndrome

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that the Office of Orphan Products Development of the US Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient SGX94 for the treatment of acute radiation syndrome (ARS).

16 Sep 2013

Helper T cells important for AIDS vaccine development

A major new finding that will significantly advance efforts to create the world's first antibody-based AIDS vaccine was published today by researchers from the La Jolla Institute for Allergy and Immunology.

13 Sep 2013

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira, the world's leading provider of injectable drugs and infusion technologies, today announced the European Commission (EC) approval of Inflectra™ (infliximab), Europe's first biosimilar monoclonal antibody (mAb) therapy. Inflectra has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

10 Sep 2013

UCLA receives multimillion-dollar gift to provide patients with innovative home health program

A multimillion-dollar gift has allowed the UCLA Division of Digestive Diseases to provide patients with an innovative home health program; supported new, minimally invasive treatment procedures; and funded state-of-the-art gastroenterology research.

10 Sep 2013

Parasites could be potential key to treating autoimmune diseases

There is a new weapon in the fight against autoimmune diseases such as Type 1 diabetes, rheumatoid arthritis, Crohn's disease and lupus, the common trait of which is an immune system that attacks its own organs and tissues.

10 Sep 2013

Scientists reveal structure of protein essential for triggering necroptosis

Scientists in Melbourne, Australia, have revealed the structure of a protein that is essential for triggering a form of programmed cell death called necroptosis, making possible the development of new drugs to treat chronic inflammatory diseases such as Crohn's disease and rheumatoid arthritis.

6 Sep 2013

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States Food and Drug Administration has granted Priority Review status for the Biologics License Application for its new investigational drug vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis.

5 Sep 2013

AARDA study reveals mothers antibodies may cause autism in babies

A new, large-scale study of more than 2,700 mothers of children with autism shows that about one in 10 mothers have antibodies in their bloodstream that react with proteins in the brain of their babies.

29 Aug 2013

TAP block procedure poses no significant risks to patients and cuts postoperative use of narcotics

Surgeons at University Hospitals Case Medical Center, Cleveland, are working to reduce serious complications that have been known to occur with colorectal operations.

29 Aug 2013

Immune Pharmaceuticals announces completion of merger with EpiCept Corporation

Immune Pharmaceuticals Inc. announced today the completion of the merger of Immune Pharmaceuticals Ltd. and EpiCept Corporation.

26 Aug 2013

Model including dozens of mutations helps clarify genetic factors involved in Crohn's disease

A statistical model accounting for dozens of different genes in combination-and the interactions between them-is an important step forward in understanding the genetic factors affecting the risk of Crohn's disease (CD), reports a study in Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America (CCFA). The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

26 Aug 2013

Understanding genetic factors that affect Crohn's disease risk

A statistical model accounting for dozens of different genes in combination—and the interactions between them—is an important step forward in understanding the genetic factors affecting the risk of Crohn's disease, reports a study in Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America.

23 Aug 2013

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

Takeda Pharmaceutical Company Limited today announced that results from two Phase 3 studies evaluating vedolizumab, an investigational humanized monoclonal antibody, for the treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease, were published in the August 22, 2013 issue of the New England Journal of Medicine.

22 Aug 2013

New antibody drug shows positive results for treating Crohn's disease, ulcerative colitis

Vedolizumab, a new intravenous antibody medication, has shown positive results for treating both Crohn's disease and ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. The findings, published in two papers, will appear in the August 22 issue of the New England Journal of Medicine (NEJM).

22 Aug 2013

Nutritionists offer more tips for making kids' lunches healthier

With the start of the school year around the corner, now is the perfect time for parents to ramp up efforts at infusing their kids' lunches with creative, healthy options. "You don't have to completely cut back on snacks and sugars to ensure that your child eats a well-balanced meal," explains Dr. Joel Lavine, chief of pediatric gastroenterology at NewYork-Presbyterian/Morgan Stanley Children's Hospital.

20 Aug 2013

Probiotic does not prevent clinical relapse in patients with Crohn's disease

Despite previous data showing beneficial effects, the probiotic Saccharomuces boulardii (S. boulardii) does not prevent clinical relapse in patients with Crohn's disease, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

16 Aug 2013

Teplizumab to block type 1 diabetes proves strikingly effective in phase 2 clinical trial

An experimental drug designed to block the advance of type 1 diabetes in its earliest stages has proven strikingly effective over two years in about half of the patients who participated in the phase 2 clinical trial.

8 Aug 2013

Nektar completes enrollment in NKTR-102 BEACON trial in patients with metastatic breast cancer

Nektar Therapeutics (NASDAQ: NKTR) today announced that enrollment is complete in the pivotal clinical study of etirinotecan pegol (NKTR-102) in patients with metastatic breast cancer.

31 Jul 2013

Researchers discover mechanism that prevents immune system from spinning out of control

A team led by a University of Arizona researcher has discovered a previously unknown mechanism that prevents the immune system from going into overdrive, shedding light not only on how our body controls its response to pathogens but on conditions such as autoimmune diseases, allergies and chronic inflammation as well.

24 Jul 2013

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

RedHill Biopharma to initiate phase III trial of RHB 104 in Crohn's disease patients

FDA grants orphan drug designation to Soligenix’s SGX94 for treatment of Acute Radiation Syndrome

Helper T cells important for AIDS vaccine development

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

UCLA receives multimillion-dollar gift to provide patients with innovative home health program

Parasites could be potential key to treating autoimmune diseases

Scientists reveal structure of protein essential for triggering necroptosis

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

AARDA study reveals mothers antibodies may cause autism in babies

TAP block procedure poses no significant risks to patients and cuts postoperative use of narcotics

Immune Pharmaceuticals announces completion of merger with EpiCept Corporation

Model including dozens of mutations helps clarify genetic factors involved in Crohn's disease

Understanding genetic factors that affect Crohn's disease risk

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

New antibody drug shows positive results for treating Crohn's disease, ulcerative colitis

Nutritionists offer more tips for making kids' lunches healthier

Probiotic does not prevent clinical relapse in patients with Crohn's disease

Teplizumab to block type 1 diabetes proves strikingly effective in phase 2 clinical trial

Nektar completes enrollment in NKTR-102 BEACON trial in patients with metastatic breast cancer

Researchers discover mechanism that prevents immune system from spinning out of control

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in